Pharsight

Alcon Labs Inc patents expiration

1. Eysuvis patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11642317 ALCON LABS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

US11596599 ALCON LABS INC Compositions and methods for ophthalmic and/or other applications
May, 2033

(9 years from now)

US11872318 ALCON LABS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Oct 26, 2023

Drugs and Companies using LOTEPREDNOL ETABONATE ingredient

Market Authorisation Date: 26 October, 2020

Treatment: A method for treating dry eye in a patient

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage

EYSUVIS family patents

Family Patents

2. Inveltys patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11872318 ALCON LABS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

US11642317 ALCON LABS INC Nanocrystals, compositions, and methods that aid particle transport in mucus
May, 2033

(9 years from now)

Drugs and Companies using LOTEPREDNOL ETABONATE ingredient

Market Authorisation Date: 22 August, 2018

Treatment: NA

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage

INVELTYS family patents

Family Patents

3. Pataday Once Daily Relief patents expiration

PATADAY ONCE DAILY RELIEF Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8791154 ALCON LABS INC High concentration olopatadine ophthalmic composition
May, 2032

(8 years from now)

US9533053 ALCON LABS INC High concentration olopatadine ophthalmic composition
May, 2032

(8 years from now)

Drugs and Companies using OLOPATADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 30 January, 2015

Treatment: Treatment of ocular itching associated with allergic conjunctivitis

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of PATADAY ONCE DAILY RELIEF before it's drug patent expiration?
More Information on Dosage

PATADAY ONCE DAILY RELIEF family patents

Family Patents

4. Simbrinza patents expiration

SIMBRINZA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9421265 ALCON LABS INC Aqueous pharmaceutical compositions containing borate-polyol complexes
Jun, 2030

(6 years from now)

US9044484 ALCON LABS INC Aqueous pharmaceutical compositions containing borate-polyol complexes
Oct, 2030

(6 years from now)

Drugs and Companies using BRIMONIDINE TARTRATE; BRINZOLAMIDE ingredient

Market Authorisation Date: 19 April, 2013

Treatment: NA

Dosage: SUSPENSION/DROPS;OPHTHALMIC

How can I launch a generic of SIMBRINZA before it's drug patent expiration?
More Information on Dosage

SIMBRINZA family patents

Family Patents